Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PEP-07 by Sentinel Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
PEP-07 by Sentinel Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
PEP-07 by Sentinel Oncology for Mantle Cell Lymphoma: Likelihood of Approval
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
PEP-07 by Sentinel Oncology for Mantle Cell Lymphoma: Likelihood of Approval
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
PEP-07 by Sentinel Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
PEP-07 by Sentinel Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...